Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Irbesartan Hydrochlorothiazide Winthrop er større end risiciene ved behandling af essentiel hypertension hos patienter, hvis blodtryk ikke kan reguleres tilfredsstillende ved hjælp af irbesartan eller hydrochlorothiazid alene.
The Committee for Medicinal Products for Human Use (CHMP) decided that Irbesartan Hydrochlorothiazide Winthrop’ s benefits are greater than its risks for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.